Haemonetics reports USD 339.38 million revenue: Haemonetics stock has 57.98 times earnings

Published on 10/17/2026 at 21:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Earnings per share hit USD 1.14 versus USD 1.09. Haemonetics stock was last at USD 118.28 on October 16, 2026, down 2.48 percent on NYSE.

Operating figures and dates

First-quarter fiscal 2027 revenue reached USD 339.38 million on August 6, 2026.
Adjusted earnings per share came to USD 1.14 versus USD 1.09 consensus.
Haemonetics stock was last at USD 118.28 on October 16, 2026, down 2.48 percent on the NYSE.
Haemonetics plans to publish second-quarter fiscal 2027 results on November 5, 2026.

HAE, US4050241003, Illustration mit AI erstellt.

Haemonetics Corporation (ISIN US4050241003) reported first-quarter fiscal 2027 revenue of USD 339.38 million on August 6, 2026, versus USD 331.17 million consensus, according to Fintel. The result remains the clearest operating marker for the stock, while the next scheduled report is November 5, 2026. Haemonetics was last at USD 118.28 on October 16, 2026 at 4:00 p.m. ET, down 2.48 percent on the NYSE.

Revenue cleared consensus

The first-quarter revenue figure exceeded the cited consensus by USD 8.21 million, or 2.48 percent. Revenue also increased 5.60 percent from the prior-year quarter, according to the same report. The comparison points to continued expansion, but the period remains the June quarter of fiscal 2027 rather than a new October result.

Earnings per share and guidance

Adjusted earnings per share reached USD 1.14 in the first quarter, compared with a USD 1.09 consensus estimate. A separate earnings-call summary said Haemonetics raised fiscal 2027 reported revenue-growth guidance to 5.00 percent to 8.00 percent and organic growth guidance to 4.00 percent to 7.00 percent, according to Squawk News on October 5, 2026.

Stock sits below its high

The USD 118.28 last price stands USD 5.49, or 4.44 percent, below the USD 123.77 52-week high and USD 69.30 above the USD 48.98 52-week low. Market capitalization was USD 5.4 billion and the price-to-earnings ratio was 57.98 as of October 16, 2026. Those figures frame the stock as a high-multiple medical technology name, with earnings delivery and the next outlook update central to valuation.

November date sets next checkpoint

Haemonetics Corporation said on September 30, 2026 that it intends to publish second-quarter fiscal 2027 results at 6:00 a.m. ET on November 5, 2026, followed by an investor call at 8:00 a.m. ET. The company describes its business as combining apheresis systems with blood-management and interventional technologies.

Price and investor perspective

The October 16 decline puts the stock below its yearly high while leaving the latest quarterly revenue above consensus. The November 5 report will provide the next dated test of the 5.00 percent to 8.00 percent reported-growth outlook.

Haemonetics was last at USD 118.28 on the NYSE on October 16, 2026 at 4:00 p.m. ET, down 2.48 percent on the day.